A precision medicine study that uses blood-based tumor genomics to optimize treatment for resectable patients with stage III colon cancer and high-risk stage IIa colon cancer.
Principal Investigator
Dott.ssa Virginia Quarà
Contact Information for Access
Phase
FASE III
Status
ATTIVO
Objective of the study
The primary objective is to demonstrate that a personalized treatment strategy, tailored based on a ctDNA-guided genomic profile, can improve clinical outcomes for patients with stage III and high-risk stage II colon cancer compared to a conventional adjuvant chemotherapy approach.
Colon Cancer
Pathologies
Gastrointestinal tumor (GI tumor)
Medication
NIVOLUMAB - IPILIMUMAB - PERTUZUMAB - TRASTUZUMAB - PANITUMUMAB - TEMOZOLOMIDE - OXALIPLATIN - IRINOTECAN - CAPECITABINE - 5-FU - LEUCOVORIN
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients with stage III or high-risk, resectable stage II colon cancer.
Back to search page